Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Oxazole SCHEMBL1144844 | 0.84 | MAPT (0.41) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL1144796 | 0.84 | KDM4E (0.46) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL31239486 | 0.84 | KDM4E (0.42) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL20844762 | 0.84 | KDM4E (0.42) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL1144835 | 0.83 | MAPT (0.42) | KDM4ELMNAGAATDP1POLB | |
| SCHEMBL24818517 | 0.80 | NOTUM (0.43) | KDM4ELMNANFKB1NFKB2RELA | |
| SCHEMBL20898134 | 0.76 | KDM4E (0.50) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL642648 | 0.74 | LMNA (0.51) | KDM4ELMNAXDHNFKB1NFKB2 | |
| SCHEMBL9181228 | 0.74 | TAS1R3 (0.58) | KDM4ELMNANFKB1NFKB2RELA | |
| SCHEMBL22300744 | 0.73 | LMNA (0.52) | KDM4ELMNAL3MBTL1CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113439084-B | Sesqui-carcinomycin analogue | 奥克兰联合服务有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20220098215-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | US | disclosed |
| EP-3917933-A1 | DUOCARMYCIN ANALOGUES | Auckland Uniservices Limited (NZ) | 2021-12-08 | — | — | EP | disclosed |
| CN-113439084-A | Duocarmycin analogs | 奥克兰联合服务有限公司 | 2021-09-24 | — | — | CN | disclosed |
| WO-2020157662-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157662-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-08-06 | — | — | WO | disclosed |
| EP-2297163-B1 | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8318762-B2 | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098215-A1 | DUOCARMYCIN ANALOGUES | TOP2A, TOP2B, MUS81 | KDM4E 406/4885LMNA 1092/4885XDH 265/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | KDM4E 1790/4885LMNA 2969/4885XDH 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.